The Swiss lower house of parliament has voted in favor of allowing US Food and Drug Administration-approved medtech to access the Swiss market.
The landmark vote in the Nationalrat by a margin of 100 votes to 79 means that parliament can instruct the Federal Council to adapt national law to accept medtech innovation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?